㈜쓰리빌리언

{
  "address": "서울특별시 강남구",
  "ceo_name": "금창원",
  "certificate": [
    {
      "cert_number": "20190300151",
      "changes": "",
      "disclosure_date": "2019-02-28",
      "first_cert_date": "2019-02-28",
      "no": "1",
      "type": "벤처투자유형",
      "valid_period": "2019-02-28 ~ 2021-02-27"
    },
    {
      "cert_number": "20210300116",
      "changes": "",
      "disclosure_date": "2021-01-28",
      "first_cert_date": "2019-02-28",
      "no": "2",
      "type": "벤처투자유형",
      "valid_period": "2021-02-28 ~ 2023-02-27"
    },
    {
      "cert_number": "20230216010020",
      "changes": "",
      "disclosure_date": "2023-02-16",
      "first_cert_date": "2019-02-28",
      "no": "3",
      "type": "벤처투자유형",
      "valid_period": "2023-02-28 ~ 2026-02-27"
    }
  ],
  "company_name": "㈜쓰리빌리언",
  "corp_no": "110111-*******",
  "financials": {
    "2022": {
      "capital_stock": 2577253000,
      "cost_of_sales": 0,
      "current_assets": 23917681000,
      "current_liabilities": 10513046000,
      "gross_profit": 828461000,
      "net_income": -3144811000,
      "net_income_bs": -3144811000,
      "non_current_assets": 3743096000,
      "non_current_liabilities": 834747000,
      "non_operating_expenses": 51647000,
      "non_operating_income": 5130831000,
      "operating_profit": -8223995000,
      "revenue": 828461000,
      "sga_expenses": 9052456000,
      "total_assets": 27660777000,
      "total_equity": 16312984000,
      "total_liabilities": 11347793000
    },
    "2023": {
      "capital_stock": 2591393000,
      "cost_of_sales": 0,
      "current_assets": 18160740000,
      "current_liabilities": 10851281000,
      "gross_profit": 2730329000,
      "net_income": -5092007000,
      "net_income_bs": -5092007000,
      "non_current_assets": 4698404000,
      "non_current_liabilities": 221566000,
      "non_operating_expenses": 105420000,
      "non_operating_income": 3365686000,
      "operating_profit": -8352273000,
      "revenue": 2730329000,
      "sga_expenses": 11082602000,
      "total_assets": 22859144000,
      "total_equity": 11786297000,
      "total_liabilities": 11072847000
    },
    "2024": {
      "capital_stock": 3168401000,
      "cost_of_sales": 0,
      "current_assets": 26119803000,
      "current_liabilities": 1873162000,
      "gross_profit": 5772098000,
      "net_income": -6571645000,
      "net_income_bs": -6571645000,
      "non_current_assets": 4095786000,
      "non_current_liabilities": 71800000,
      "non_operating_expenses": 1115105000,
      "non_operating_income": 1962549000,
      "operating_profit": -7419089000,
      "revenue": 5772098000,
      "sga_expenses": 13191187000,
      "total_assets": 30215589000,
      "total_equity": 28270627000,
      "total_liabilities": 1944962000
    }
  },
  "industry": "의학 및 약학 연구개발업",
  "investment": [
    {
      "amount": "6,999,000,000",
      "changes": "6,999,000,000",
      "date": "2022-03-31"
    },
    {
      "amount": "4,500,000,000",
      "changes": "4,500,000,000",
      "date": "2022-01-28"
    },
    {
      "amount": "500,000,000",
      "changes": "500,000,000",
      "date": "2022-01-28"
    },
    {
      "amount": "4,000,003,000",
      "changes": "4,000,003,000",
      "date": "2020-12-17"
    }
  ],
  "main_products": "희귀유전질병 진단 서비스",
  "phone": "010-4095-****",
  "years": [
    2024,
    2023,
    2022
  ]
}